Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Sellas Life Sciences Group
National Institutes of Health Clinical Center (CC)
CellCentric Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AbbVie
OHSU Knight Cancer Institute
Prelude Therapeutics
AbbVie